🚀 VC round data is live in beta, check it out!
HUTCHMED (China) Valuation Multiples
Discover revenue and EBITDA valuation multiples for HUTCHMED (China) and similar public comparables like Anhui Anke Biotechnology, Dianthus Therapeutics, Pfizer India, AstraZeneca Pharma India and more.
HUTCHMED (China) Overview
About HUTCHMED (China)
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Founded
2000
HQ
Employees
1.8K
Website
Sectors
Financials (LTM)
EV
$1B
HUTCHMED (China) Financials
HUTCHMED (China) reported last 12-month revenue of $566M and negative EBITDA of ($15M).
In the same LTM period, HUTCHMED (China) generated $231M in gross profit, ($15M) in EBITDA losses, and $383M in net income.
Revenue (LTM)
HUTCHMED (China) P&L
In the most recent fiscal year, HUTCHMED (China) reported revenue of $630M and EBITDA of $14M.
HUTCHMED (China) expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $566M | XXX | $630M | XXX | XXX | XXX |
| Gross Profit | $231M | XXX | $281M | XXX | XXX | XXX |
| Gross Margin | 41% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | ($15M) | XXX | $14M | XXX | XXX | XXX |
| EBITDA Margin | (3%) | XXX | 2% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | (6%) | XXX | XXX | XXX |
| Net Profit | $383M | XXX | $38M | XXX | XXX | XXX |
| Net Margin | 68% | XXX | 6% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
HUTCHMED (China) Stock Performance
HUTCHMED (China) has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
HUTCHMED (China)'s stock price is $2.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | $0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHUTCHMED (China) Valuation Multiples
HUTCHMED (China) trades at 1.9x EV/Revenue multiple, and (71.7x) EV/EBITDA.
EV / Revenue (LTM)
HUTCHMED (China) Financial Valuation Multiples
As of March 7, 2026, HUTCHMED (China) has market cap of $2B and EV of $1B.
Equity research analysts estimate HUTCHMED (China)'s 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HUTCHMED (China) has a P/E ratio of 6.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | (71.7x) | XXX | 77.4x | XXX | XXX | XXX |
| EV/EBIT | 27.9x | XXX | (26.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | 6.2x | XXX | 62.6x | XXX | XXX | XXX |
| EV/FCF | (28.3x) | XXX | (62.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified HUTCHMED (China) Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
HUTCHMED (China) Margins & Growth Rates
HUTCHMED (China)'s revenue in the last 12 month grew by 19%.
HUTCHMED (China)'s revenue per employee in the last FY averaged $0.3M.
HUTCHMED (China)'s rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HUTCHMED (China)'s rule of X is 44% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
HUTCHMED (China) Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | (13%) | XXX | XXX | XXX |
| EBITDA Margin | (3%) | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | (220%) | XXX | (248%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 16% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 51% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
HUTCHMED (China) Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Anhui Anke Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Dianthus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Pfizer India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca Pharma India | XXX | XXX | XXX | XXX | XXX | XXX |
| Ocular Therapeutix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HUTCHMED (China) M&A Activity
HUTCHMED (China) acquired XXX companies to date.
Last acquisition by HUTCHMED (China) was on XXXXXXXX, XXXXX. HUTCHMED (China) acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by HUTCHMED (China)
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHUTCHMED (China) Investment Activity
HUTCHMED (China) invested in XXX companies to date.
HUTCHMED (China) made its latest investment on XXXXXXXX, XXXXX. HUTCHMED (China) invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by HUTCHMED (China)
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout HUTCHMED (China)
| When was HUTCHMED (China) founded? | HUTCHMED (China) was founded in 2000. |
| Where is HUTCHMED (China) headquartered? | HUTCHMED (China) is headquartered in China. |
| How many employees does HUTCHMED (China) have? | As of today, HUTCHMED (China) has over 1K employees. |
| Who is the CEO of HUTCHMED (China)? | HUTCHMED (China)'s CEO is Johnny Cheng Chig FUNG. |
| Is HUTCHMED (China) publicly listed? | Yes, HUTCHMED (China) is a public company listed on HKEX. |
| What is the stock symbol of HUTCHMED (China)? | HUTCHMED (China) trades under 00013 ticker. |
| When did HUTCHMED (China) go public? | HUTCHMED (China) went public in 2021. |
| Who are competitors of HUTCHMED (China)? | HUTCHMED (China) main competitors are Anhui Anke Biotechnology, Dianthus Therapeutics, Pfizer India, AstraZeneca Pharma India. |
| What is the current market cap of HUTCHMED (China)? | HUTCHMED (China)'s current market cap is $2B. |
| What is the current revenue of HUTCHMED (China)? | HUTCHMED (China)'s last 12 months revenue is $566M. |
| What is the current revenue growth of HUTCHMED (China)? | HUTCHMED (China) revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of HUTCHMED (China)? | Current revenue multiple of HUTCHMED (China) is 1.9x. |
| Is HUTCHMED (China) profitable? | No, HUTCHMED (China) is not profitable. |
| What is the current EBITDA of HUTCHMED (China)? | HUTCHMED (China) has negative EBITDA and is not profitable. |
| What is HUTCHMED (China)'s EBITDA margin? | HUTCHMED (China)'s last 12 months EBITDA margin is (3%). |
| What is the current EV/EBITDA multiple of HUTCHMED (China)? | Current EBITDA multiple of HUTCHMED (China) is (71.7x). |
| What is the current FCF of HUTCHMED (China)? | HUTCHMED (China)'s last 12 months FCF is ($39M). |
| What is HUTCHMED (China)'s FCF margin? | HUTCHMED (China)'s last 12 months FCF margin is (7%). |
| What is the current EV/FCF multiple of HUTCHMED (China)? | Current FCF multiple of HUTCHMED (China) is (28.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.